Changes in aldehyde dehydrogenase-1 expression during neoadjuvant chemotherapy predict outcome in locally advanced breast cancer

Muhammad Alamgeer, Vinod Ganju, Beena Kumar, Jane Fox, Stewart A Hart, Michelle White, Marion T Harris, John Stuckey, Zdenka Prodanovic, Michal E Schneider, David Neil Watkins

Research output: Contribution to journalArticleResearchpeer-review

43 Citations (Scopus)


INTRODUCTION: Although neoadjuvant chemotherapy (NAC) for locally advanced breast cancer can improve operability and local disease control, there is a lack of reliable biomarkers that predict response to chemotherapy or long-term survival. Since expression of ALDEHYDE DEHYDROGENASE-1 (ALDH1) is associated with the stem-like properties of self-renewal and innate chemoresistance in breast cancer, we asked whether expression in serial tumour samples treated with NAC could identify women more likely to benefit from this therapy. METHODS: Women with locally advanced breast cancer were randomly assigned to receive four cycles of anthracycline-based chemotherapy, followed by four cycles of taxane therapy (Arm A), or the same regimen in reverse order (Arm B). Tumour specimens were collected at baseline, after four cycles, and then at surgical resection. ALDH1 expression was determined by immunohistochemistry and correlated with tumour response using Fisher s exact test while Kaplan-Meier method was used to calculate survival. RESULTS: A hundred and nineteen women were enrolled into the study. Fifty seven (48 ) were randomized to Arm A and 62 (52 ) to Arm B. Most of the women (90 ) had ductal carcinoma and 10 had lobular carcinoma. Of these, 26 (22 ) achieved a pathological complete response (pCR) after NAC. There was no correlation between baseline ALDH1 expression and tumour grade, stage, hormone receptor, HER2 status and Ki67 index. ALDH1 negativity at baseline was significantly associated with cPR (p = 0.004). The presence of ALDH1(+) cells in the residual tumour cells in non-responding women was strongly predictive of worse overall survival (p = 0.024). Moreover, serial analysis of specimens from non-responders showed a marked increase in tumour-specific ALDH1 expression (p = 0.028). Overall, there was no survival difference according to the chemotherapy sequence. However, poorly responding tumours from women receiving docetaxel chemotherapy showed an unexpected significant increase in ALDH1 expression. CONCLUSIONS: ALDH1 expression is a useful predictor of chemoresistance. The upregulation of ALDH1 after NAC predicts for poor survival in locally advanced breast cancer. Although the chemotherapy sequence had no effect on overall prognosis, our results suggest that anthracycline-based chemotherapy may be more effective at targeting ALDH1(+) breast cancer cells.Trial registration: ACTRN12605000588695.
Original languageEnglish
Article numberR44
Number of pages13
JournalBreast Cancer Research
Issue number2
Publication statusPublished - 2014

Cite this